Clinical Analysis for Patients with AML Treated after Allo-HSCT.
10.19746/j.cnki.issn.1009-2137.2020.04.005
- Author:
Qing-Yun WANG
1
;
Yu-Jun DONG
1
;
Ze-Yin LIANG
1
;
Yue YIN
1
;
Wei LIU
1
;
Wei-Lin XU
1
;
Yu-Hua SUN
1
;
Na HAN
1
;
Yuan LI
2
;
Han-Yun REN
3
Author Information
1. Department of Hematology, Peking University First Hospital, Beijing 100034, China.
2. Department of Hematology, Peking University First Hospital, Beijing 100034, China,E-mail: drliyuan75@163.com.
3. Department of Hematology, Peking University First Hospital, Beijing 100034, China,E-mail: renhy0813@163.com.
- Publication Type:Journal Article
- MeSH:
Disease-Free Survival;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myeloid, Acute;
Neoplasm Recurrence, Local;
Remission Induction;
Retrospective Studies
- From:
Journal of Experimental Hematology
2020;28(4):1105-1114
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze risk factors that affect survival and relapse of AML patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and to investigate the therapy choices after AML relapse.
METHODS:Clinical data of 180 AML patients achieved complete remission (CR) before HSCT from January 2009 to December 2018 treated in our center were analyzed retrospectively. Risk factors for survival and relapse after allo-HSCT were analyzed by COX regression.
RESULTS:Among 180 AML patients, 134 survived (74.4%), 46 patients died (25.6%), and 40 patients relapsed (22.2%). The rate of overall survival (OS), event-free survival (EFS) and cumulative rate of relapse in 5-years was 74.3%、42.5% and 25.0%, respectively. High-risk, adverse cytogenetics, CR at HSCT and no cGvHD were independent risk factors that affect OS. CR at HSCT, high-risk were independent risk factors that affect EFS. High-risk, MRD after one course of induction therapy, adverse cytogenetics and no cGVHD were independent risk factors that affect relapse. The OS rate of relapse patients could be improved by the usage of hypomethylation agents combined with G-CSF mobilized donor lymphocyte infusion (DLI), and 2-year OS rate was 62.5%.
CONCLUSION:The survival rate of AML is greatly improved by allo-HSCT, but relapse is still one of the most important factors that influence survival of the AML patients. The maintenance therapy of hypomethylation agents combined with DLI may be a new effective treatment option for patients who relapse after HSCT.
